title: Profiling tumor counterattack: do Fas ligand-containing microvesicles reduce anticancer immunity?
authors.affiliation: Division of Immunology and Hematopoiesis, Sidney Kimmel Comprehensive Cancer Center, Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
authors.forename: Osnat
authors.initials: O
authors.lastname: Bohana-Kashtan
authors.forename: Curt I
authors.initials: CI
authors.lastname: Civin
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000276:immunology* / Q000473:pathology; D022162:Cytoplasmic Vesicles / Q000378:metabolism*; D053222:Fas Ligand Protein; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D009062:Mouth Neoplasms / Q000097:blood / Q000276:immunology* / Q000473:pathology
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins